Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

FRESENIUS SE & CO. KGAA

(FRE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Fresenius : Lifts FY21 Group Earnings Outlook After 'Very Strong' H1

08/02/2021 | 01:09am EDT


ę MT Newswires 2021
All news about FRESENIUS SE & CO. KGAA
09/27VIFOR PHARMA : Gets Japanese Marketing Authorization For Avacopan in Autoimmune Kidney Dis..
MT
09/23European ADRs Move Sharply Higher in Thursday Trading
MT
09/23FRESENIUS MEDICAL CARE AG & CO. KGAA : Release according to Article 40, Section 1 of the W..
DJ
09/22FRESENIUS SE : Berenberg reaffirms its Buy rating
MD
09/22FRESENIUS SE : Gets a Buy rating from Goldman Sachs
MD
09/21FRESENIUS SE : DZ Bank reaffirms its Buy rating
MD
09/20FMC FRESENIUS MEDICAL CARE AG & CO K : Receives a Sell rating from Jefferies
MD
09/20PRESS RELEASE : Rentschler Biopharma appoints Dr. Christian Schetter as Chief Scientific O..
DJ
09/17FRESENIUS : Bank of America – Global Healthcare Conference (PDF, 5.96 MB)
PU
09/17FRESENIUS MEDICAL CARE : Selects JMS Co. as Distributor of Home Dialysis Systems in Japan
MT
More news
Analyst Recommendations on FRESENIUS SE & CO. KGAA
More recommendations
Financials
Sales 2021 37 435 M 43 723 M 43 723 M
Net income 2021 1 824 M 2 131 M 2 131 M
Net Debt 2021 22 787 M 26 614 M 26 614 M
P/E ratio 2021 12,7x
Yield 2021 2,08%
Capitalization 23 078 M 27 004 M 26 954 M
EV / Sales 2021 1,23x
EV / Sales 2022 1,10x
Nbr of Employees 312 734
Free-Float 73,1%
Chart FRESENIUS SE & CO. KGAA
Duration : Period :
Fresenius SE & Co. KGaA Technical Analysis Chart | FRE | DE0005785604 | MarketScreener
Technical analysis trends FRESENIUS SE & CO. KGAA
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Last Close Price 41,36 €
Average target price 49,88 €
Spread / Average Target 20,6%
EPS Revisions
Managers and Directors
Stephan Sturm President & Chief Executive Officer
Rachel Clare Empey Chief Financial Officer
Wolfgang Kirsch Chairman-Supervisory Board
Sebastian Biedenkopf Legal, Compliance & Human Resources Director
Klaus-Peter MŘller Independent Member-Supervisory Board